News

Announcing Our Seed Funding Round!

News / November 6, 2023

We are delighted to announce that we have just closed our funding round. We are on a mission to reshape the healthcare landscape, and this investment will play a crucial role in advancing our goals. With this support, we are better equipped to develop cutting-edge digital therapies and broaden our impact on patients’ lives.

Share this article

2023 is not the easiest time in startup history to be raising funding and we are incredibly proud that our investor and eventually partner put their trust in us and joined us on our mission to transform the healthcare landscape by developing prescription digital therapeutics (PDTs) for the management, treatment, and prevention of chronic diseases.

With a team of experts spanning software engineering, clinical medicine, pharmaceutical industry, and private health insurance, we are committed to enhancing the quality of life for patients suffering from chronic diseases. We believe that software has the potential to revolutionize medicine by providing non-chemical and non-biological therapies that not only halt disease progression but also reverse it by addressing the root causes.

What’s next?

This investment marks a significant milestone in our journey, supporting our vision of becoming a globally recognized digital therapeutics company. The funds raised will expedite the development of innovative software therapies for chronic diseases, further solidifying our position at the forefront of this transformative field.

In addition to advancing our groundbreaking research and development efforts, we will also leverage this investment to expand our presence in the United Kingdom. Tesu Health’s participation in the Cambridge Life Sciences Market Access Programme, run by Locate Cambridge, is set to receive a significant boost. This strategic move will strengthen our operations within the UK’s life sciences hub, allowing us to engage with leading healthcare and research institutions and foster collaborative efforts.

Tesu Health extends its heartfelt gratitude to its investor and partner for their trust and commitment to the company’s vision. This seed investment represents a significant step forward in the quest to revolutionize healthcare with innovative software solutions.

Hasan Avcu – CEO

İlker Tosun – CMO

Gürkan Caner Birer – CTO

Announcing Our Seed Funding Round! Read More »

Tesu Health Joins Cambridge Life Sciences Market Access Programme

News / July 19, 2023

Tesu Saglik Teknolojileri A.S. (“Tesu Health“) has been chosen as one of the ten companies worldwide to participate in the prestigious Cambridge Life Sciences Market Access Programme, administered by Locate Cambridge. This remarkable achievement positions Tesu Health as a frontrunner in the rapidly evolving landscape of life sciences and underscores the region’s pivotal role as a gateway to the UK market.

Share this article

Locate Cambridge, the representative body for the combined authority of Cambridge, Peterborough, and Fenland, has meticulously selected Tesu Health and nine other innovative companies from across the globe to receive VIP support in establishing their presence in the Cambridge and Peterborough region.

The Cambridge and Peterborough region is renowned for its world-class research institutions, a diverse talent pool, cutting-edge innovation, and an ecosystem rich in business support and investment opportunities.

Tesu Health, with its commitment to improving global healthcare through technological advancements, is set to benefit significantly from this unparalleled opportunity. The company’s innovative solutions align perfectly with the region’s life sciences ecosystem, positioning Tesu Health to make a lasting impact on healthcare worldwide.

The Cambridge Life Sciences Market Access Programme provides Tesu Health with a unique platform to access resources, forge strategic partnerships, and tap into investment funds essential for scaling its operations.

Tesu Health’s selection for this program reaffirms the company’s dedication to transforming healthcare and improving patient outcomes. As Tesu Health embarks on this exciting journey in the heart of the UK’s life sciences hub, the company aims to leverage the region’s resources to accelerate its mission of making high-quality healthcare accessible to all.

Tesu Health Joins Cambridge Life Sciences Market Access Programme Read More »

Two New R&D Projects in Chronic Diseases

News / July 7, 2023

Tesu Saglik Teknolojileri A.S. (“Tesu Health“), today announced that two of its research and development projects have been approved by Cube Incubation Center R&D Projects Evaluations Committee of Teknopark Istanbul. The projects, which will start in September, will focus on the development of prescription digital therapeutics (PDTs) for adult patients with type 2 diabetes and for overweight & obese adult patients. Tesu Health, with a commitment to developing innovative solutions, is determined to create a robust pipeline of products, with a focus on prescription digital therapeutics.

Share this article

Chronic diseases have posed a considerable challenge to healthcare systems worldwide for an extended period. Conditions such as type 2 diabetes and obesity have reached epidemic proportions, necessitating innovative and sustainable solutions. Tesu Health is rising to the occasion, aiming to revolutionize treatment and management through cutting-edge prescription digital therapeutics.

Tesu Health’s research and development project for adult patients with type 2 diabetes aims to provide personalized, effective, and accessible solutions for patients. Prescription digital therapeutics involve the use of software programs to deliver evidence-based interventions. These interventions are tailored to each patient’s unique needs, helping manage their condition and improve overall health. Tesu Health’s innovative approach will empower patients to take control of their diabetes through user-friendly digital tools.

Obesity is another chronic condition that has seen alarming rates of growth in recent years. It is often associated with a host of health complications, including heart disease, hypertension, and type 2 diabetes. Tesu Health’s second project focuses on prescription digital therapeutics for overweight and obese adult patients. This project will utilize advanced technology to create personalized interventions, supporting patients in achieving and maintaining a healthy weight. By addressing the root causes of obesity, Tesu Health aims to enhance the overall well-being of individuals struggling with this condition.

The potential of prescription digital therapeutics lies in their ability to provide targeted, evidence-based interventions while remaining accessible and convenient. Patients can engage with these therapies from the comfort of their homes, reducing the burden on healthcare facilities and enhancing the continuity of care.

Furthermore, these digital solutions can adapt to the individual needs and progress of each patient, offering a level of personalization that traditional treatments often lack. With Tesu Health’s projects, adult patients with type 2 diabetes and those battling obesity will have access to tools that empower them to take control of their health journeys.

Tesu Health’s approval of two groundbreaking research and development projects for type 2 diabetes and obesity represents a commendable effort in the fight against chronic diseases. By harnessing the power of prescription digital therapeutics, Tesu Health aims to provide personalized and effective solutions for patients, empowering them to lead healthier lives.

Two New R&D Projects in Chronic Diseases Read More »

The Founder Institute Spring 2023 FI Core Program

News / February 27, 2023

Tesu Health has recently been accepted into The Founder Institute‘s Istanbul – Turkey Spring 2023 FI Core Program. This is exciting news for the company as it means they will have access to some of the world’s top entrepreneurs and mentors.

Share this article

The Founder Institute is an American business incubator and startup launch program that was founded in Palo Alto, California in 2009. It has since expanded to over 180 cities in more than 65 countries and has helped over 6,500 entrepreneurs raise over $1.75B in funding.

The Founder Institute‘s mission is to empower talented and motivated people to build impactful technology companies worldwide. The FI Core Program is a structured accelerator program designed to help early-stage startups validate their business ideas, develop their products, and prepare for fundraising. It provides startups with access to a global network of mentors, investors, and peers, as well as a structured curriculum and weekly feedback sessions.

This program will provide Tesu Health with valuable resources and support to help us achieve our goals. This is a significant step for Tesu Health, and our acceptance into the Istanbul – Turkiye Spring 2023 FI Core Program is a testament to the company’s potential impact on the healthcare industry in Turkiye and beyond.

The Founder Institute Spring 2023 FI Core Program Read More »

First Patient Enrolled in TH001_1001

News / February 23, 2023

Tesu Health is pleased to announce that the first patient has been enrolled in the clinical trial (NCT05668819) TH001_1001. The trial evaluates TH-001 versus standard of care in adult patients with prediabetes over a 90-day treatment period with the primary outcome measures being the mean change from baseline in HbA1c (%), FPG (mg/dL), and 2-hour 75 g OGTT (mg/dL) at day 90 between groups.

Share this article

In October 2022 Turkish Medicines and Medical Devices Agency of the Ministry of Health granted Tesu Health approval for a prospective, randomized, controlled clinical trial. The study allows Tesu Health to collect safety and effectiveness data to support a CE Mark certification of TH-001 as a medical device upon completion of the study.

The trial is being led by Principal Investigator Seda Sancak Nurdan, MD, Professor of Endocrinology at the Fatih Sultan Mehmet Training and Research Hospital in Istanbul, Turkiye. An important step in the study was achieved when the first patient was enrolled by the Principal Investigator.

Enrolling the first subject in this important trial is another key milestone for Tesu Health’s clinical program, and we are very pleased to be collaborating with the Fatih Sultan Mehmet Training and Research Hospital research team in evaluating our investigational medical device TH-001 in an indication with a significant unmet medical need.

For more information about the clinical trial TH001_1001 please visit ClinicalTrials.gov.

First Patient Enrolled in TH001_1001 Read More »

Bayer Digital Health Startups Map

News / July 27, 2022

Tesu Health has recently been included in Bayer’s Digital Health Startups Map. The map is part of Bayer’s Startup Acceleration Program G4A Turkiye and aims to promote innovation in the ecosystem by introducing and supporting startups in the field of health.

Share this article

The updated map features 105 startups founded by entrepreneurs in Turkiye and operating in various categories related to health, such as Healthy Living, Hospital & Pharmacy Solutions, Biotechnology & R&D, Easy Diagnosis & Early Diagnosis, Child Health, and Wearable Technology & IoT. Among these startups, 18 have been selected for Bayer’s G4A Turkiye program, which has been running for 5 years.

Through the program, Bayer provides startups with grants, mentorship, training, and collaboration support, to help them to grow and succeed. The program has already seen great success, with 9 of the startups that received investment reaching a total company valuation of 90.4 million dollars.

Tesu Health‘s inclusion in Bayer’s Digital Health Startups Map is a significant achievement for the company and highlights the importance of our potential to contribute to the growth of the digital health domain. As Bayer provides communication support to all startups by sharing the map on various channels and platforms, it is expected that Tesu Health’s visibility and potential for partnerships and collaborations will increase. The support provided by Bayer through the G4A Turkiye program is a testament to the company’s commitment to promoting innovation and contributing to the growth of the healthcare industry.

Bayer Digital Health Startups Map Read More »

Biocube Accelerator Program

News / May 27, 2022

Tesu Health is proud to announce its acceptance into the Biocube Accelerator Program, a thematic infrastructure operation and accelerator model project supported by the Istanbul Development Agency. This program is designed to provide entrepreneurs and startups in the biotechnology, pharmaceuticals, and medical devices industries with the resources they need to bring innovative ideas to market and create economic value.

Share this article

As a participant in the Biocube Accelerator Program, Tesu Health will have access to a wide range of resources and support systems, including business, operation, and marketing mechanisms. These resources will enable us to transform our innovative ideas into economic products and create added value in the healthcare industry.

We are excited to be working with Boğaziçi University, Teknopark Istanbul, and İSEK-Istanbul Health Industry Cluster, who are all committed to providing the best possible support to entrepreneurs in the biotechnology, pharmaceuticals, and medical devices industries. Their expertise and guidance will be invaluable as we work to develop our products and grow our business.

At Tesu Health, we are dedicated to improving the lives of patients and healthcare providers through the development of innovative technologies. With the support of the Biocube Accelerator Program, we look forward to bringing our ideas to market and making a positive impact in the healthcare industry.

We are grateful for this opportunity and are excited to take part in the Biocube Accelerator Program. We believe that this program will provide us with the resources and support we need to succeed in our mission of improving healthcare for all.

Biocube Accelerator Program Read More »

TUBITAK 1512-Entrepreneurship Capital Support Award

News / February 6, 2022

Tesu Saglik Teknolojileri A.S. (“Tesu Health“) is proud to announce that we have been honored with the Scientific and Technological Research Council of Turkey (TUBITAK) 1512-Entrepreneurship Capital Support Award for our “Development of evidence-based, prescription digital therapeutics for the treatment of prediabetic individuals” project (project ID: 2210830).

Share this article

The esteemed 1512 Entrepreneurship Support Program, which aims to foster innovation and entrepreneurship by providing capital and other resources, supports entrepreneurs at every stage of their venture, from idea inception to market entry. It is our firm belief that this recognition will provide us with invaluable resources and a platform for continued growth, helping us to transform our technology and innovation-driven business ideas into high-value enterprises that create skilled employment opportunities.

During the first call of 2021, a total of 2395 entrepreneurs submitted business ideas, and Tesu Health was among the applicants. Of these, 1114 entrepreneurs were selected to receive phase 1 support from 63 Implementing Organizations. Subsequently, the business plans of 305 entrepreneurs whose proposals were approved by the Implementing Organizations underwent rigorous evaluation within the scope of stage 2 panels organized by TÜBİTAK. Following the evaluation process, which involved experts from academia, industry, and investment, 132 entrepreneurs were deemed eligible to receive stage 2 support of up to 200,000 TL within the framework of the first call of 2021.

We are honored to be among the recipients of this prestigious award and are committed to utilizing the resources to achieve our mission of transforming healthcare through technology and innovation.

TUBITAK 1512-Entrepreneurship Capital Support Award Read More »

Announcing Our Seed Funding Round!

Tesu Health Joins Cambridge Life Sciences Market Access Programme

Two New R&D Projects in Chronic Diseases

The Founder Institute Spring 2023 FI Core Program

First Patient Enrolled in TH001_1001

Bayer Digital Health Startups Map

Biocube Accelerator Program

TUBITAK 1512-Entrepreneurship Capital Support Award

NAVIGATION

SOCIAL MEDIA

USEFUL LINKS